In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Opinion|Videos|January 31, 2025 (Updated: January 31, 2025)
Clinical Insights on Use of CAR-T Therapy
This segment highlights clinical experiences with ide-cel in the second-line setting, focusing on observed improvements in efficacy and quality of life, as well as challenges in administration
Advertisement
Video content above is prompted by the following:
- Can you share your experience with using ide-cel in the second-line setting?
- What improvements in efficacy and quality of life have you observed?
- What challenges have you faced in administering this treatment?
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Advertisement
Advertisement
Trending on CancerNetwork
1
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
2
Closing the HCC Surveillance Gap in MASLD Without Cirrhosis
3
Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC
4
Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis
5